Isavuconazole as primary antifungal prophylaxis in pediatric hematological patients: a clinical and pharmacokinetic analysis. (PubMed, Antimicrob Agents Chemother) - Jun 27, 2026 - "Concomitant use of CYP3A4-interacting agents (e.g., ruxolitinib) was not associated with increased toxicity or isavuconazole level alterations. In this retrospective cohort of high-risk pediatric hematology patients, isavuconazole used as primary antifungal prophylaxis showed favorable safety, consistent drug exposure, and no breakthrough IFDs. These findings support further prospective evaluation of isavuconazole in pediatric prophylactic strategies."
Journal • PK/PD data • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Oncology • Pediatrics • Transplantation • CYP3A4
|
|
Arcangelo Prete; Caterina Campoli; Davide Leardini; Edoardo Muratore; Federico Pea; Francesca Gottardi; Francesco Baccelli; Francesco Venturelli; Gennaro Pagano; Gianluca Bossù; Maddalena Giannella; Martina Colli; Milo Gatti; Pierluigi Viale; Riccardo Masetti; Tamara Belotti
|